Technology
Health
Pharmaceutical

Sage Therapeutics

$163.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.81 (3.03%) Today
-$0.01 (-0.01%) After Hours

Why Robinhood?

You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!

About

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Employees
637
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
7.45B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
509.47K
High Today
$164.75
Low Today
$159.65
Open Price
$160.19
Volume
208.85K
52 Week High
$188.82
52 Week Low
$79.88

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2014 IPO
US

News

NPRMar 21

New Postpartum Depression Drug Could Be Hard To Access For Moms Most In Need

New Postpartum Depression Drug Could Be Hard To Access For Moms Most In Need toggle caption AleksandarNakic/Getty Images One in nine women in the United States suffer from depression after childbirth. For some women, postpartum depression is so bad that they struggle to care for their children and may even consider or attempt suicide. This week, the Food and Drug Administration approved a new drug that can help, the first drug approved specifically for postpartum depression. While researchers and clinici...

334
CNBCMar 20

Sage Therapeutics CEO: Getting the first postpartum depression drug approved

Sage Therapeutics CEO: Getting the first postpartum depression drug approved 21 Mins Ago Jim Cramer talks with Sage Therapeutics CEO Jeff Jonas about the biopharma company's Zulresso drug for postpartum depression and how it could help mothers....

165
InvestorPlaceMar 20

Sage Stock Pops on FDA Approval for Postpartum Depression Drug

Sage Therapeutics (NYSE: SAGE ) is popped yesterday on FDA approval of its postpartum depression drug — the first of its kind. So far, SAGE stock is up 3%, but this on the back of a more than 70% run up year-to-date in anticipation of the news. Source: Shutterstock Postpartum depression is a sometimes life-threatening condition that can happen before or after a woman gives birth to a child. In serious cases, she may harm herself or her child as a result. It is estimated that as many as one in nine women w...

279

Earnings

-$3.38
-$2.37
-$1.37
-$0.36
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.